Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | Profit After Tax at 14% of Revenue(3rd Quarter & 9 Months, FY 2019 Consolidated Results).......
By: Ajanta Pharma Q3 FY 2019 performance highlights (compared to Q3 FY 2018) · Income from operations at Rs. 485 cr. against Rs. 587 cr., down 17%. · EBITDA at Rs. 107 cr. against Rs. 198 cr., down 46%; EBITDA at 22% of revenue. · Profit after tax at Rs. 67 cr., against Rs. 147 cr., down 55%; PAT at 14% of revenue. 9 Months FY 2019 performance highlights (compared to 9 months FY 2018) · Income from operations at Rs. 1,540 cr. against Rs. 1,601 cr., down 4%. · EBITDA at Rs. 439 cr. against Rs. 509 cr., down 14%; EBITDA at 29% of revenue. · Profit after tax at Rs. 298 cr., against Rs. 374 cr., down 20%; PAT at 19% of revenue. Commenting on the results, Mr. Yogesh Agrawal, Managing Director said: "This quarter was bit challenging for the company which was the result of pipeline filling in corresponding quarter previous year which got normalized. Our sales in all our key markets continue to post satisfactory growths reflecting strong inherent fundamentals of the brands which are built over the years. This quarter also saw significant drop in the anti-malarial business due to changing conditions of this business segment. Operational expenses of two new additional manufacturing facilities at Dahej & Guwahati during the year also weighed on the profitability growths. As we ramp up the capacity utilization of these facilities in coming years, we expect to see the cost rationalization and better efficiency in tax. During 9 moths, we have filed 8 ANDA's and expect to file healthy no. of ANDA's in Q4 which should pave way for sound revenues on their approval and commercialization." India Q3 FY 2019, India sales was Rs. 174 cr. (against Rs. 160 cr.), up 9%. 9 Months FY 2019, India sales was Rs. 531 cr. (against Rs. 481 cr.) posting growth of 10%. As per IMS MAT December 2018, we have posted healthy growth of 16% in Cardiology (segment growth of 11%), 13% in Ophthalmology (segment growth of 9%), 9% in Dermatology (segment growth of 14%) and 20% in Pain Management (segment growth of 9%). Exports Q3 FY 2019, total export sales were Rs. 304 cr. (against Rs. 415 cr.) posting de-growth of 27%. · Emerging Market branded generic sales was Rs. 188 cr. (against Rs. 250 cr.) posting 25% de-growth. Out of which: § Africa branded generic sales was Rs. 64 cr. (against Rs. 86 cr.) posting 26% de-growth. § Asia branded generic sales was Rs. 121 cr. (against Rs. 161 cr.) posting 25% de-growth. · US generic sales was Rs. 66 cr. (against Rs. 71 cr.) posting 7% de-growth. · Africa Institution sales was Rs. 50 cr. (against Rs. 94 cr.) posting 47% de-growth. 9 Months FY 2019, total export sales were Rs. 981 cr. (against Rs. 1,086 cr.) posting de-growth of 10%. · Emerging Market branded generic sales was Rs. 625 cr. (against Rs. 613 cr.) posting 2% growth. Out of which: § Africa branded generic sales was Rs. 232 cr. (against Rs. 246 cr.) posting 6% de-growth. § Asia branded generic sales was Rs. 385 cr. (against Rs. 361 cr.) posting 7% growth. · US generic sales was Rs. 207 cr. (against Rs. 152 cr.) posting 36% growth. · Africa Institution sales was Rs. 149 cr. (against Rs. 321 cr.) posting 53% de-growth. In US, during 9 Months FY 2019, we received 7 ANDA final approval; 3 tentative approvals; and filed 8 ANDA with US FDA. Out of 24 final ANDA approvals, we have commercialized 21 products. We hold 4 tentative approvals and 17 ANDAs are awaiting US FDA approval. Company plans to file 10-12 ANDAs during this financial year. R&D During Q3 FY 2019, R&D expenses were Rs. 45 cr., (Q3 FY 2018 Rs. 43 cr.) which is 9% of operating revenue. During 9 Months FY 2019, R&D expenses were Rs. 136 cr., (9 Months FY 2018 Rs. 138 cr.) which is 9% of operating revenue. About Ajanta Pharma Limited Ajanta Pharma is a speciality pharmaceutical formulation company having branded generic business in India and emerging markets, generic business in US and institution business in Africa. Many of company's products are 1st to market and are leading in their sub-therapeutic segments. Company's state of the art R&D centres for formulation development and API are located at Mumbai, having a team of 850+ scientists. Company has 7 world class manufacturing facilities located in India and Mauritius. For last 5 financial years, company has posted healthy performance with its consolidated total income growing at 15% CAGR and net profit at 19% CAGR. For more details visit www.ajantapharma.com For regular updates follow us on twitter– www.twitter.com/ For specific queries, contact: Rajeev Agarwal Tel: +91 22 66061377 Email: rajeev.agarwal@ Abhineet Kumar Tel: +91 22 66061814 Email: abhineet.kumar@ Corporate Identity Number (CIN): L24230MH1979PLC022059 Safe Harbour Statement (http://www.ajantapharma.com/ End
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number